FUCASO

Beyond's analysis on FUCASO

• 2026-09-27 — IASO Bio's FUCASO demonstrates near‑complete response rates in heavily pretreated Chinese patients with relapsed/refractory plasma cell neoplasms

Recent news mentioning FUCASO

• 2026-09-27 — 2026 IMS | IASO Bio Presented FUCASO China Real-World Data
• 2026-09-25 — 2026 IMS | Updated FUMANBA-1 Analysis of IASO Bio's FUCASO Reveals That In Vivo Durable Persistence of CAR-T cells Is Associated with Sustained MRD Negativity and Delayed Disease Progression

Appears alongside

• IMS
• IASO
• China
• MRD

Browse the full archive →